Amgen Inc. (formerly Applied Molecular Genetics Inc.[5][6]) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.[2] Amgen, which is one of the world's largest biotechnology companies, was established in Newbury Park, California in 1980, where its world headquarters are located.[7][8] It had 5,125 employees in Thousand Oaks as of 2017, which made up 7.5% of the city's total employment.[9] It is the largest employer in Ventura County.[8][10] Amgen has attracted hundreds of scientists to the Newbury Park area. Focused on the cutting edge of molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.[11] The word Amgen is a portmanteau of the company's original name, Applied Molecular Genetics, which became the official name of the company in 1983 (three years after incorporation and coincident with its initial public offering). The company's first chief executive officer, from 1980, was co-founder George B. Rathmann, followed by Gordon M. Binder in 1988,[12] followed by Kevin W. Sharer in 2000.[13] Robert A. Bradway became Amgen’s president and chief executive officer in May 2012 following Sharer's retirement.[14] The company has made at least five major corporate acquisitions. The following is an illustration of the company's mergers, acquisitions, spin-offs and historical predecessors: {{Expansion depth limit exceeded|1={{Expansion depth limit exceeded|1=Amgen(Founded 1983 as Applied Molecular Genetics) }} }} {{Expansion depth limit exceeded|1=Synergen Inc(Acq 1994) }} Kinetix Pharmaceuticals Inc(Acq 2000) Immunex Corporation(Acq 2002) Tularik Inc (Acq 2004) Abgenix Inc(Acq 2006) Avidia Inc(Acq 2006) Alantos Pharmaceuticals(Acq 2007) Ilypsa Inc(Acq 2007) Alantos Pharmaceuticals Holdings Inc(Acq 2007) BioVex Group Inc(Acq 2011) Laboratório Químico Farmacêutico Bergamo Ltda(Acq 2011) Micromet Inc(Acq 2012) Mustafa Nevzat İlaç(Acq 2012) KAI Pharmaceuticals(Acq 2012) deCODE genetics(Acq 2012) Onyx Pharmaceuticals(Acq 2013) NextCODE genetics(Spun off 2013) Dezima Pharma(Acq 2015) Catherex(Acq 2015) Amgen's approved drugs or therapeutic biologicals include: As of December 2013, Amgen had 11 drugs in Phase III clinical trials.[61] In November 2014 the company announced it was halting all trials of rilotumumab in advanced gastric cancer patients after one of the trials found more deaths in those who took the compound with chemotherapy, than those without.[62] Later in the same week, the company (in conjunction with AstraZeneca) reported positive results for brodalumab in a phase III trial comparing the compound with ustekinumab and a placebo in treating psoriasis.[63] In March 2015, the company announced it would license its Phase II candidate drug AMG 714 to developer Celimmune who plan to develop the anti-IL-15 monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease.[64] In June 2015 Amgen presented Phase 2 clinical trial data for their anti-CGRP antibody AMG 334 for migraine, approved for sale as AIMOVIG in 2019.[65]